Denali Therapeutics Announces First Patient Dosed in Phase 1b Study of DNL747 for Alzheimer’s Disease
Denali Therapeutics Announces First Patient Dosed in Phase 1b Study of DNL201 for Parkinson’s Disease
CENTOGENE and Denali Therapeutics Announce Strategic Collaboration to Recruit LRRK2 Patients for Clinical Trials
QIMC Reports Multiple Elevated Hydrogen Mud-Gas Readings Over 100m-250m Interval of DDH-26-04, Including a Peak Hydrogen Reading of 16.0%, Two Hydrogen Readings of 13.5%, and Nine Readings at or Above 5% Hydrogen
Oreterra Completes Airborne Geophysical Survey of the Kinkaid Cu-Au-Ag Project, Nevada, Identifies Significant New Porphyry Target
